Multiple Sclerosis and Related Disorders, volume 55, pages 103157

T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers

Doriana Landi 2
Gaia Cola 2
Vincenzo Malagnino 1
Elisabetta Teti 1
Daniela Fraboni 3
Laura Campogiani 1
M. Andreoni 1
G. A. Marfia
Publication typeJournal Article
Publication date2021-10-01
Quartile SCImago
Q1
Quartile WOS
Q2
Impact factor4
ISSN22110348, 22110356
General Medicine
Neurology
Neurology (clinical)
Abstract
Disease modifying therapies for multiple sclerosis (MS) can impair the specific immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Specifically, it is recognized that ocrelizumab reduces or abrogates anti-SARS-CoV-2 antibody production after natural infection or vaccination, while very little is known about T-cell responses.We developed an interferon (IFN)-γ release assay (IGRA) to detect T-cell responses specific to SARS-CoV-2 after overnight stimulation of whole blood with peptide libraries covering the immunodominant sequence domains of the Spike glycoprotein (S) and the Nucleocapsid phosphoprotein (N).Five patients with MS receiving ocrelizumab treatment for at least 1 year and recovered from SARS-CoV-2 infection were enrolled in the study. Despite the absence or the very low concentration of anti-S antibodies, a T-cell response was detectable in all the five MS patients. These results are in accordance with the marked reduction of peripheral B-lymphocyte absolute counts induced by ocrelizumab, that, conversely, did not affect peripheral blood T-lymphocyte subset absolute and relative counts and CD4/CD8 ratio.The detection of specific T-cell responses to SARS-CoV-2 in patients receiving B-cell depleting therapies represents a useful tool to improve the diagnostic approach in SARS-CoV-2 infection and to accurately assess the immunological response after natural infection or vaccination.

Top-30

Citations by journals

1
2
3
4
5
Multiple Sclerosis and Related Disorders
5 publications, 16.13%
Multiple Sclerosis Journal
3 publications, 9.68%
Neurology and Therapy
2 publications, 6.45%
Neurology: Neuroimmunology and NeuroInflammation
2 publications, 6.45%
International Journal of Molecular Sciences
2 publications, 6.45%
Frontiers in Immunology
2 publications, 6.45%
Journal of Neurology
2 publications, 6.45%
Current Opinion in Neurology
1 publication, 3.23%
Biomedicines
1 publication, 3.23%
Nature Reviews Neurology
1 publication, 3.23%
Annals of Neurology
1 publication, 3.23%
Clinical and Experimental Immunology
1 publication, 3.23%
European Journal of Neurology
1 publication, 3.23%
Multiple Sclerosis Journal - Experimental Translational and Clinical
1 publication, 3.23%
Journal of Clinical Medicine
1 publication, 3.23%
Journal of the Neurological Sciences
1 publication, 3.23%
Nature Immunology
1 publication, 3.23%
Russian Chemical Reviews
1 publication, 3.23%
1
2
3
4
5

Citations by publishers

1
2
3
4
5
6
Springer Nature
6 publications, 19.35%
Elsevier
6 publications, 19.35%
SAGE
4 publications, 12.9%
Multidisciplinary Digital Publishing Institute (MDPI)
4 publications, 12.9%
Wolters Kluwer Health
3 publications, 9.68%
Wiley
3 publications, 9.68%
Frontiers Media S.A.
2 publications, 6.45%
Cold Spring Harbor Laboratory
1 publication, 3.23%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 3.23%
1
2
3
4
5
6
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Iannetta M. et al. T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers // Multiple Sclerosis and Related Disorders. 2021. Vol. 55. p. 103157.
GOST all authors (up to 50) Copy
Iannetta M., Landi D., Cola G., Malagnino V., Teti E., Fraboni D., Buccisano F., Grelli S., Coppola L., Campogiani L., Andreoni M., Marfia G. A., Sarmati L. T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers // Multiple Sclerosis and Related Disorders. 2021. Vol. 55. p. 103157.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.msard.2021.103157
UR - https://doi.org/10.1016/j.msard.2021.103157
TI - T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers
T2 - Multiple Sclerosis and Related Disorders
AU - Iannetta, Marco
AU - Landi, Doriana
AU - Cola, Gaia
AU - Malagnino, Vincenzo
AU - Teti, Elisabetta
AU - Fraboni, Daniela
AU - Buccisano, Francesco
AU - Grelli, Sandro
AU - Coppola, Luigi
AU - Campogiani, Laura
AU - Andreoni, M.
AU - Marfia, G. A.
AU - Sarmati, L.
PY - 2021
DA - 2021/10/01 00:00:00
PB - Elsevier
SP - 103157
VL - 55
SN - 2211-0348
SN - 2211-0356
ER -
BibTex
Cite this
BibTex Copy
@article{2021_Iannetta,
author = {Marco Iannetta and Doriana Landi and Gaia Cola and Vincenzo Malagnino and Elisabetta Teti and Daniela Fraboni and Francesco Buccisano and Sandro Grelli and Luigi Coppola and Laura Campogiani and M. Andreoni and G. A. Marfia and L. Sarmati},
title = {T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers},
journal = {Multiple Sclerosis and Related Disorders},
year = {2021},
volume = {55},
publisher = {Elsevier},
month = {oct},
url = {https://doi.org/10.1016/j.msard.2021.103157},
pages = {103157},
doi = {10.1016/j.msard.2021.103157}
}
Found error?